BrightSpring Health Services, Inc. (BTSG) AI Stock Analysis

• Market Cap: $8.51B
• Dividend Yield: N/A
• Average Volume (3M): 2.66M
• Price to Earnings (P/E): 39.8
• Beta (1Y): 1.14
• Revenue Growth: 17.23%
• EPS Growth: N/A
• Country: US
• Employees: 37,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.33
• Shares Outstanding: 193,549,160
• 10 Day Avg. Volume: 3,727,533
• 30 Day Avg. Volume: 2,664,323
• PEG Ratio: -0.04
• Price to Book (P/B): 4.05
• Price to Sales (P/S): 0.59
• P/FCF Ratio: 19.22
• Enterprise Value/Market Cap: 1.32
• Enterprise Value/Revenue: 0.87
• Enterprise Value/Gross Profit: 7.42
• Enterprise Value/Ebitda: 24.52
• 1Y Price Target: $51.70
• Price Target Upside: 20.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): 1.55
• Revenue Forecast (FY): $14.85B

• Rating: 70 Outperform
• Price Target: $46.00 ▲(6.80% Upside)
• Action: Upgraded Date: 03/18/26
• Date: Action: Upgraded 03/18/26

The score is driven primarily by improving financial performance (profitability, cash flow, and leverage repair) and a positive earnings outlook with strong 2026 growth and margin-expansion guidance. The main constraints are a high valuation multiple with no dividend support and mixed near-term technical momentum, alongside quantified IRA/generic and customer-transition headwinds.

Positive Factors

Balance-sheet repair

Material deleveraging through 2025 meaningfully reduces financial risk and increases strategic flexibility. A much lower debt load and recovered equity base support opportunistic M&A, targeted buybacks or debt paydown and make the firm more resilient to reimbursement or volume shocks over the next 2–6 months.

Strong cash generation

Sustained FCF in 2025 that closely tracked reported earnings improves earnings quality and funds capital allocation priorities. Reliable cash generation supports continued debt reduction and operational investments; though historical volatility warrants monitoring, the 2025 cash profile materially strengthens solvency and execution ability.

Pharmacy scale and pipeline

Large-scale pharmacy operations and rapid specialty/infusion growth create durable competitive advantages: purchasing power, payor leverage, and operational scale. Management's LDD pipeline and repeated launches (ongoing targeted LDD launches) provide a structural avenue to higher-margin specialty volumes over the medium term.

Negative Factors

IRA and generic reimbursement headwinds

Quantified multi-hundred-million dollar headwinds from IRA and brand-to-generic conversions represent structural reimbursement pressure. These reductions in realized reimbursement could compress margins and offset volume gains, forcing sustained operational offsets or margin recovery initiatives to hit guidance.

Customer concentration and script disruption

Loss of a large customer and deliberate exits of uneconomic contracts reduce revenue stability and increase payer/customer concentration risk. Such structural client churn can depress utilization and margins until replacements scale, making near-term recovery dependent on new contract wins and retention execution.

Acquisition integration & margin uncertainty

Acquired branches add revenue but come with lower immediate margins and require integration investment. The uncertain timeline to reach company-average margins and one-off integration costs risk delaying expected margin expansion and make 2026 margin targets sensitive to execution and timing.

BrightSpring Health Services, Inc. Business Overview & Revenue Model

Company Description

BrightSpring Health Services, Inc. operates a home and community-based healthcare services platform in the United States. The company's platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It serves patients through clinical providers and pharmacists. BrightSpring Health Services, Inc. was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. The company was founded in 1974 and is based in Louisville, Kentucky.

How the Company Makes Money

BrightSpring makes money primarily by delivering healthcare services and dispensing/providing pharmacy-related services that are reimbursed by government programs, managed care plans, and other payors. In its Provider Services segment, revenue is generated by providing home- and community-based care (including home health and hospice) and billing payors on a per-visit, per-episode, or other contracted reimbursement basis depending on the service line and payer arrangement; payments are typically tied to eligibility, authorizations, and clinical documentation requirements. In its Pharmacy Solutions segment, revenue is generated through dispensing prescription drugs and providing pharmacy services to patients and care settings (including long-term care and other complex-care channels); the company earns revenue from prescription reimbursement and service fees, with economics influenced by payer contracting, formulary and reimbursement terms, pharmacy service arrangements with facilities/providers, and drug purchasing costs. Across both segments, earnings are affected by patient volumes, payer mix (e.g., Medicare/Medicaid vs. commercial), reimbursement rates, labor and staffing costs, regulatory compliance requirements, and the company’s ability to manage clinical quality and operational efficiency under value-based or managed-care arrangements where applicable. Specific material partnerships and quantified revenue breakdowns are null.

BrightSpring Health Services, Inc. Financial Statement Overview

Summary

2025 shows a clear rebound with positive net income, strong operating/free cash flow (~$490M), and sharply improved leverage (much lower debt-to-equity). Offsets include thin and pressured margins (gross margin down to ~11.8%; net margin ~1.5%), decelerating revenue growth, and historically volatile cash-flow conversion.

Income Statement

Revenue has grown consistently from 2020 to 2025 (with 2025 growth at ~4%), indicating steady demand, but growth has clearly decelerated versus earlier years. Profitability improved meaningfully in 2025 with positive net income (~$191M) after losses in 2022–2024, yet overall margins remain thin (2025 net margin ~1.5%, EBITDA margin ~3.6%). Gross margin has also trended down over time (from ~18–19% in 2020–2021 to ~11.8% in 2025), suggesting higher cost pressure or mix shift even as bottom-line results rebounded.

Balance Sheet

Leverage improved sharply by 2025, with debt-to-equity falling to ~0.13 from very elevated levels in 2021–2023 (roughly ~4–6x), which materially reduces financial risk. Equity has also expanded versus the low point in 2023, supporting a healthier capital base. The key watch-out is that returns on equity were negative in 2022–2024 due to net losses, though 2025 shows a return to solid profitability (ROE ~10%), indicating balance-sheet repair is translating into improved earnings power.

Cash Flow

Cash generation strengthened substantially in 2025 with operating cash flow of ~$490M and free cash flow of ~$490M, a major improvement from 2024 (low operating cash flow and negative free cash flow). Free cash flow also covered net income well in 2025 (free cash flow roughly in-line with earnings), supporting earnings quality. However, cash-flow performance has been volatile (including negative operating cash flow in 2022), and the reported operating cash flow coverage ratio remains relatively low in most years, which suggests cash conversion and working-capital dynamics still warrant monitoring.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	12.91B	11.27B	8.83B	7.72B	6.70B
Gross Profit	1.52B	1.59B	1.43B	1.35B	1.25B
EBITDA	459.53M	398.13M	349.52M	391.80M	433.34M
Net Income	190.67M	-18.06M	-154.60M	-53.91M	49.80M
Balance Sheet
Total Assets	6.41B	5.93B	5.53B	5.44B	5.51B
Cash, Cash Equivalents and Short-Term Investments	88.37M	61.25M	13.07M	13.63M	46.73M
Total Debt	2.84B	2.90B	3.67B	3.68B	3.77B
Total Liabilities	4.53B	4.27B	4.92B	4.66B	4.71B
Stockholders Equity	1.88B	1.65B	584.74M	754.78M	774.82M
Cash Flow
Free Cash Flow	394.69M	-57.14M	137.26M	-74.77M	210.90M
Operating Cash Flow	490.17M	23.77M	210.78M	-4.65M	270.17M
Investing Cash Flow	-310.18M	-140.24M	-134.43M	45.36M	-1.19B
Financing Cash Flow	-152.77M	164.65M	-76.91M	-73.81M	705.22M

BrightSpring Health Services, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 43.07
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTSG, the sentiment is Positive. The current price of 43.07 is above the 20-day moving average (MA) of 40.90, above the 50-day MA of 39.90, and above the 200-day MA of 30.81, indicating a bullish trend. The MACD of 0.39 indicates Negative momentum. The RSI at 60.27 is Neutral, neither overbought nor oversold. The STOCH value of 68.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BTSG.

BrightSpring Health Services, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PGNY	72 Outperform	$1.49B	37.40	11.37%	―	11.41%	8.70%
BTSG	70 Outperform	$8.51B	39.79	10.71%	―	17.23%	―
PRVA	70 Outperform	$2.69B	126.39	0.01%	―	19.01%	38.68%
HNGE	64 Neutral	$3.51B	-6.96	-132.16%	―	50.67%	-578.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVH	46 Neutral	$305.89M	-0.85	-69.22%	―	-16.65%	-71.92%

BrightSpring Health Services, Inc. Corporate Events

BrightSpring Announces Secondary Offering and Share Repurchase Plan

On March 2, 2026, BrightSpring Health Services, Inc. entered into an underwriting agreement with KKR-affiliated and management selling stockholders and Goldman Sachs & Co. LLC for an underwritten secondary offering of 20,000,000 common shares at $41.15 per share. The transaction, which closed on March 4, 2026, involved only existing holders selling shares, generated no primary proceeds for the company apart from option-exercise cash, and included a company share repurchase of 1,464,807 shares from the underwriter, signaling an adjustment in the shareholder base and modest capital deployment toward buybacks.

Under the agreement, all shares in the offering were sold by the selling stockholders, with the underwriter waiving fees on the portion repurchased by the company. The deal was executed under an automatic shelf registration previously filed with the SEC and included customary representations, covenants, closing conditions, and indemnification obligations, underscoring a standard capital markets transaction that facilitates sponsor and management liquidity while slightly reducing the public float via the buyback.

The most recent analyst rating on (BTSG) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on BrightSpring Health Services, Inc. stock, see the BTSG Stock Forecast page.